These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 18189290)

  • 61. Racial and Ethnic Disparities in Cancer Survival: The Contribution of Tumor, Sociodemographic, Institutional, and Neighborhood Characteristics.
    Ellis L; Canchola AJ; Spiegel D; Ladabaum U; Haile R; Gomez SL
    J Clin Oncol; 2018 Jan; 36(1):25-33. PubMed ID: 29035642
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy.
    Wright JL; Reis IM; Zhao W; Panoff JE; Takita C; Sujoy V; Gomez CR; Jorda M; Franceschi D; Hurley J
    Breast; 2012 Jun; 21(3):276-83. PubMed ID: 22178596
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Assessment of 25-Year Survival of Women With Estrogen Receptor-Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy: A Secondary Analysis of Data From the Stockholm Tamoxifen Randomized Clinical Trial.
    Dar H; Johansson A; Nordenskjöld A; Iftimi A; Yau C; Perez-Tenorio G; Benz C; Nordenskjöld B; Stål O; Esserman LJ; Fornander T; Lindström LS
    JAMA Netw Open; 2021 Jun; 4(6):e2114904. PubMed ID: 34190995
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.
    Cortesi L; De Matteis E; Cirilli C; Marcheselli L; Proietto M; Federico M
    Tumori; 2012 Nov; 98(6):743-50. PubMed ID: 23389361
    [TBL] [Abstract][Full Text] [Related]  

  • 65. High prevalence of triple-negative tumors in an urban cancer center.
    Lund MJ; Butler EN; Bumpers HL; Okoli J; Rizzo M; Hatchett N; Green VL; Brawley OW; Oprea-Ilies GM; Gabram SG
    Cancer; 2008 Aug; 113(3):608-15. PubMed ID: 18484596
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Relationship of established risk factors with breast cancer subtypes.
    McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
    Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
    Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
    Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Breast cancer with triple-negative phenotype in the Russian patient population. Clinical and morphologic features].
    Zhukova LG
    Vopr Onkol; 2015; 61(2):189-94. PubMed ID: 26087596
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prognostic Significance of Tumor Subtypes in Women With Breast Cancer According to Stage: A Population-based Study.
    Leone JP; Leone J; Zwenger AO; Vallejo CT; Leone BA
    Am J Clin Oncol; 2019 Jul; 42(7):588-595. PubMed ID: 31166208
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of estrogen receptor, progesterone receptor and HER2 results in concurrent ipsilateral samples with invasive breast carcinoma: a retrospective study of 246 biopsies from 119 patients.
    Singh K; Wang Y; Marketkar S; Kalife ET; Steinhoff MM
    Hum Pathol; 2017 Jul; 65():123-132. PubMed ID: 28457730
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients.
    Dunnwald LK; Rossing MA; Li CI
    Breast Cancer Res; 2007; 9(1):R6. PubMed ID: 17239243
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series.
    McCormack VA; Joffe M; van den Berg E; Broeze N; Silva Idos S; Romieu I; Jacobson JS; Neugut AI; Schüz J; Cubasch H
    Breast Cancer Res; 2013; 15(5):R84. PubMed ID: 24041225
    [TBL] [Abstract][Full Text] [Related]  

  • 73. HER2 status and disparities in luminal breast cancers.
    Holowatyj AN; Ruterbusch JJ; Ratnam M; Gorski DH; Cote ML
    Cancer Med; 2016 Aug; 5(8):2109-16. PubMed ID: 27250116
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.
    Chen XS; Ma CD; Wu JY; Yang WT; Lu HF; Wu J; Lu JS; Shao ZM; Shen ZZ; Shen KW
    Tumori; 2010; 96(1):103-10. PubMed ID: 20437866
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Influence of clinical, societal, and treatment variables on racial differences in ER-/PR- breast cancer survival.
    Roseland ME; Schwartz K; Ruterbusch JJ; Lamerato L; Krajenta R; Booza J; Simon MS
    Breast Cancer Res Treat; 2017 Aug; 165(1):163-168. PubMed ID: 28547656
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015.
    Kong X; Liu Z; Cheng R; Sun L; Huang S; Fang Y; Wang J
    JAMA Netw Open; 2020 Oct; 3(10):e2020303. PubMed ID: 33074325
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors.
    Parise CA; Caggiano V
    Breast Cancer Res Treat; 2017 Oct; 165(3):743-750. PubMed ID: 28689363
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
    Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
    Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment and survival disparities by ethnicity in New Zealand women with stage I-III breast cancer tumour subtypes.
    Lawrenson R; Lao C; Campbell I; Harvey V; Seneviratne S; Edwards M; Elwood M; Scott N; Kidd J; Sarfati D; Kuper-Hommel M
    Cancer Causes Control; 2017 Dec; 28(12):1417-1427. PubMed ID: 29027594
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pathology of Senegalese breast cancers.
    Fitzpatrick MB; Rendi MH; Kiviat NB; Toure P; Dem A; Sow PS; Hawes SE; Feng Q; Allison KH
    Pan Afr Med J; 2019; 34():67. PubMed ID: 31819783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.